Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Stuart J ConnollyGanesan KarthikeyanMpiko NtsekheAbraham HaileamlakAhmed El SayedAlaa El GhamrawyAlbertino DamascenoAlvaro AvezumAntonio M L DansBernard GituraDayi HuEmmanuel R KamanziFathi MakladyGolden FanaJ Antonio Gonzalez-HermosilloJohn MusukuKhawar KazmiLiesl ZühlkeLillian GondweChangsheng MaMaria PaniaguaOkechukwu S OgahOnkabetse J Molefe-BaikaiPeter LwabiPilly ChilloSanjib K SharmaTantchou T J CabralWadea M TarhuniAlexander BenzMartin van EikelsAmy KrolDivya PattathKumar BalasubramanianSumathy RangarajanChinthanie RamasundarahettigeBongani MayosiSalim Yusufnull nullPublished in: The New England journal of medicine (2022)
Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).
Keyphrases
- atrial fibrillation
- cardiovascular events
- oral anticoagulants
- catheter ablation
- left atrial
- direct oral anticoagulants
- left atrial appendage
- rheumatoid arthritis
- coronary artery disease
- heart failure
- pulmonary hypertension
- venous thromboembolism
- percutaneous coronary intervention
- cardiovascular disease
- pulmonary embolism
- type diabetes
- cell therapy
- stem cells
- acute coronary syndrome